Neoadjuvant treatment combining the immunotherapy drug durvalumab with chemotherapy allowed most patients with resectable or borderline resectable non-small-cell lung cancer to proceed to surgery, according to results from the phase 2 MDT-BRIDGE trial. The findings, published in Nature Medicine and presented at the ESMO Congress 2026, point to encouraging rates of pathological complete response, the state in which no cancer cells are found in tissue removed during surgery.
The trial was conducted across multiple countries and enrolled patients whose tumors could be removed surgically or were on the border of being operable. Patients received durvalumab together with chemotherapy before surgery. After this neoadjuvant phase, a multidisciplinary team reassessed each patient to decide the next step. In most cases, this reassessment led to an operation.
Patients whose tumors were judged unresectable did not simply leave the study without further options. They continued with chemoradiotherapy followed by consolidative durvalumab. According to the trial report, this continuation did not raise any additional safety concerns. For clinicians, that detail matters because it suggests the approach can be applied to a broader group of patients without adding new risks beyond those already recognized for each treatment component.
A separate study in Nature, drawn from the NeoCOAST-2 program and published on October 25, 2026, examined circulating tumor DNA clearance and outcomes in resectable lung cancer. That research addresses a related question: whether tracking tumor DNA in the blood can help show how well treatment before surgery is working. Taken together, the two publications reflect growing interest in using pre-surgical therapy to shrink or eliminate disease and in measuring that response more precisely.
Lung cancer remains one of the leading causes of cancer death, and surgery is a central option for patients whose disease has not spread widely. Treatments given before an operation aim to improve outcomes by reducing the cancer burden and potentially eliminating microscopic disease. The MDT-BRIDGE results add evidence that durvalumab combined with chemotherapy can fit into this approach for patients who are on the boundary of operability.
The trial's reported outcomes are preliminary in the sense of being a phase 2 study, which typically evaluates activity and safety rather than confirming long-term survival benefit. Larger phase 3 studies would be needed to establish whether the gains in surgical access and pathological response translate into longer survival. The results nonetheless give oncologists and surgeons a clearer picture of how this regimen performs when multidisciplinary teams guide decisions after initial treatment.
20
